Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Aurinia Pharmaceuticals, Inc. has moved from very attractive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 11.23, and a PEG ratio of 0.10, indicating potential growth at a reasonable price.
In comparison to its peers, Aurinia's P/E ratio of 20.87 is notably higher than that of Rhythm Pharmaceuticals, Inc., which has a P/E of -36.41, highlighting the relative valuation strength of Aurinia. Additionally, the company’s ROCE of 99.51% and ROE of 16.33% suggest strong profitability compared to its industry. Over the past year, Aurinia has outperformed the S&P 500 with a return of 60.86% versus the index's 14.08%, reinforcing its current valuation stance.